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Abstract: Hydroxy fatty acids are known to cause cell cycle arrest and apoptosis. The best studied of
them, 9-hydroxystearic acid (9-HSA), induces apoptosis in cell lines by acting through mechanisms
involving different targets. Using mass spectrometry-based lipidomic approaches, we show in this
study that 9-HSA levels in human colorectal tumors are diminished when compared with normal
adjacent tissue. Since this decrease could be compatible with an escape mechanism of tumors from
9-HSA-induced apoptosis, we investigated different features of the utilization of this hydroxyfatty
acid in colon. We show that in colorectal tumors and related cell lines such as HT-29 and HCT-116,
9-HSA is the only hydroxyfatty acid constituent of branched fatty acid esters of hydroxyfatty acids
(FAHFA), a novel family of lipids with anti-inflammatory properties. Importantly, FAHFA levels in
tumors are elevated compared with normal tissue and, unlike 9-HSA, they do not induce apoptosis
of colorectal cell lines over a wide range of concentrations. Further, the addition of 9-HSA to colon
cancer cell lines augments the synthesis of different FAHFA before the cells commit to apoptosis,
suggesting that FAHFA formation may function as a buffer system that sequesters the hydroxyacid
into an inactive form, thereby restricting apoptosis.
Keywords: colorectal cancer; hydroxystearic acid; fatty acid esters of hydroxy fatty acids; apoptosis
1. Introduction
Colorectal cancer is a frequent cause of death due to late tumor presentation, rapid progression,
and metachronous metastases [1]. Although hugely diverse in type and etiology, colon cancer cells
often share as common characteristics a high rate of cell division and activated anti-apoptotic genes. In
this regard, several studies have described mechanisms through which tumor cells escape apoptosis,
some of which may involve lipid signaling [2–4].
Previous studies have shown that low micromolar concentrations of the hydroxy fatty acid
9-HSA exert cytostatic effects on highly proliferating cells such as human HT-29 colorectal cancer
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cells, causing cell arrest at the G0 phase of the cell cycle. At higher doses, 9-hydroxystearic acid
(9-HSA) is a strong inducer of cell death by apoptosis. Increased 9-HSA levels may interfere with cell
cycle kinetics by interacting with the cdc2 kinase complex and with p21, a potent cyclin-dependent
kinase inhibitor controlled by the tumor suppressor protein p53 [5–7]. The effects of 9-HSA on
cancer cell proliferation and differentiation have been attributed to inhibition of histone deacetylase-1
by a mechanism likely involving direct fatty acid/enzyme interaction. Such inhibition results in
down-regulation of p53-dependent gene activation, driving cells to apoptosis [8–10]. In addition,
9-HSA-treated colon cancer cell lines have been found to be unable to re-enter the cell cycle and to
proliferate in response to epidermal growth factor stimulation [9]. Collectively, these data raise the
intriguing possibility that tumor cells may possess regulatory mechanisms to keep 9-HSA at low levels
so as to avoid entering into apoptosis.
Recently, Yore et al. [11] described the existence of a novel family of lipids, called branched fatty
acid esters of hydroxy fatty acids (FAHFA), and found that they were elevated in murine adipocytes
overexpressing the GLUT-4 glucose transporter [12]. Structurally, FAHFA consists of a hydroxylated
fatty acid, the hydroxyl moiety of which is esterified with palmitic acid (16:0), stearic acid (18:0), or
oleic acid (18:1n−9) (Figure 1). Interestingly, the most abundant FAHFA in plasma and adipose tissue
are those which contain 9-HSA, and 9-HSA-containing FAHFA possess anti-inflammatory properties
and positively modulate insulin sensitivity and glucose tolerance in adipose tissue [11,12].
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investigate the biochemical and biological properties of this molecule in the development of 
colorectal cancer, using as a model both primary tumors and cell lines. Here, we identify FAHFA in 
human colon cancers and propose a novel mechanism by which colorectal cancer cells divert 
cytotoxic 9-HSA to non-toxic FAHFA as a strategy to escape from apoptosis. 
2. Results and Discussion 
Growing evidence suggests that the monohydroxy fatty acid 9-HSA may inhibit cell 
proliferation by acting at different levels [5–10]. We began the current work by setting up conditions 
to identify and quantify 9-HSA in human colorectal cancer samples. Our initial assumption was that, 
in order to keep cell proliferation active, 9-HSA levels in cancer cells would be significantly lower 
Figure 1. 9-Hydroxystearic acid (9-HSA)-containing branched fatty acid esters of hydroxy fatty acids
(FAHFA).
To the best of our knowledge, FAHFA have not been studied in tumor cells, and their possible
effects on cell survival and proliferation have neither been documented. Due to the aforementioned
pro-apoptotic properties of 9-HSA in colon cancer cells, the objective of this research was to investigate
the biochemical and biological properties of this molecule in the development of colorectal cancer,
using as a model both primary tumors and cell lines. Here, we identify FAHFA in human colon cancers
and propose a novel mechanism by which colorectal cancer cells divert cytotoxic 9-HSA to non-toxic
FAHFA as a strategy to escape from apoptosis.
2. Results and Discussion
G wing eviden e suggests that th monohydroxy fat y a id 9-HSA may inhibit cell proliferation
by acting at different levels [5–10]. We began the current work by setting up conditions to identify
and quantify 9-HSA in human colorectal cancer samples. Our initial assumption was that, in order
to keep cell proliferation active, 9-HSA levels in cancer cells would be significantly lower than those
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of surrounding healthy tissue. Samples from colorectal cancer patients were obtained the day of
scheduled surgery, and they were analyzed for hydroxylated fatty acid content by gas chromatography
coupled to electron impact mass spectrometry (GC/MS). 9-HSA, as a trimethylsilyl (TMS) derivative,
was found to resolve well in GC from 12-HSA, an isomer present at low levels in castor oil and other
edible plant oils (Figure 2A). Since our own preliminary measurements confirmed that 12-HSA is
not detectable in our samples (see below), we utilized this isomer as an internal standard for the
quantification of 9-HSA. Figure 2B shows the merged electron impact fragmentation spectra of both
9-HSA and 12-HSA as TMS derivatives. Fragmentation of 9-HSA-TMS yielded the m/z 73 fragment that
is common to all TMS derivatives, plus two diagnostic fragments of m/z 229 and 259, which represent
the fragmentation of the molecule at both sides of the carbon carrying the hydroxyl group (Figure 2B,
noted in orange). Similarly, 12-HSA-TMS yielded the m/z 73 fragment and two diagnostic fragments at
m/z 187 and 301 (Figure 2B, noted in blue).
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Figure 2. Characterization of free and esterified 9-HSA by mass spectrometry. (A) Gas chromatography
(GC) separation of 9-HSA and 12-HSA methyl esters as trimethylsilyl (TMS) derivatives. (B) Electron
impact fragmentation pattern of 9-HSA (orange) superimposed to the 12-HSA fragmentation pattern
(blue). Due to structural similarity, both compounds share many fragments (black). However, the
position of the hydroxyl group can be unambiguously established by the fragments m/z 229 and 259 for
9-HSA, and m/z 187 and 301 for 12-HSA. The other major fragment of m/z 73 is common to all TMS
derivatives. (C) Collision-induced dissociation of the major phospholipid species PE(O-18:0/9-HSA),
as analyzed by liquid chromatography/mass spectrometry (LC/MS). Fragments produce by the
generation of the carboxylic anion of 9-HSA (m/z 299.3) and its neutral lo s as a ketene (m/z 466.3)
are observed, confirming th t 9-HSA is sterified at the sn-2 position of the glycerol backbone of the
phospholipid molecule.
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Once this workflow was established, 9-HSA levels in colorectal cancer tumor samples were
measured. Tumor samples were found to contain significantly lower amounts of 9-HSA than normal
tissue samples (tissue sections adjacent to the tumor) (Figure 3). All tumor samples examined (n = 11)
contained less 9-HSA than their normal adjacent counterparts, and this reduction affected both the
free fatty acid as well as the phospholipid-esterified forms of the molecule (Figure 3). Importantly,
no fragments other than those characteristic of 9-HSA (m/z 229 and 259) were identified in any of the
samples analyzed, thus indicating that 9-HSA is the only hydroxylated fatty acid present at measurable
quantities in our samples. Analysis of the distribution of esterified 9-HSA among cellular lipids
revealed that the fatty acid was present only in phospholipids; 9-HSA was conspicuously absent of all
neutral lipid classes, including mono- di- or tri-acylglycerol and cholesterol esters.
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after lipid class separ tion and TMS derivatization. Data are expressed as means ± SEM (n = 11).
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In the next series of experi ents, the distribution of 9-HSA a ong phospholipid olecular
species was measured by liquid chromatography coupled to mass spectrometry (LC/MS). Identification
of 9-HSA-containing species was carried out by determining the formation of a frag ent of m/z
299, corresponding to the hydroxystearoyl fragment, in precursor-ion scan experiments. Structural
identification of the glycerophospholipids was achieved by looking at the fragments and/or neutral
losses obtained in product-ion scan experiments. Fatty chains within phospholipids are designated
by their number of carbons:double bonds. A designation of O- before the first fatty chain indicates
that the sn-1 position is ether-linked [13]. Analysis of healthy tissue samples adjacent to the tumors
revealed the presence of 13 glycerophospholipid species containing 9-HSA (Figure 4A).
While 9-HS was detected in all phospholipid classes examined, in relative terms, presence of
the fatty acid in PE predominated. This is consistent with previous data in platelets showing that
PE phospholipids are prone to contain oxidized fatty acids derived from arachidonic acid [14–16].
Consistent with the sharp decreases of 9-HSA already observed with GC/MS (Figure 3), tumor samples
showed a general decrease in all phospholipid classes examined. The decrease was particularly
pronounced in the case of PC and PI, which fell below detection levels in the tumor samples (Figure 4B).
Although analyses by triple quadrupole mass spectrometry do not allow unambiguous assignation
of a given fatty acid to either the sn-1 or sn-2 positions of the glycerol backbone, it is worth noting that
three of the major 9-HSA-containing species detected are of the plasmanyl type (sn-1 ether-linked)
(Figure 4A). In these phospholipids, 9-HSA is necessarily present at the sn-2 position, which raises the
possibility that sn-2 may constitute, in general terms, a preferred position for the fatty acid. In Figure 2C
it was shown the MS/MS ion fragmentation of the major 9-HSA-containing species, PE(O-18:0/9-HSA).
Note the fragment corresponding to 9-HSA as a carboxylate ion (m/z 299.3) and the ion resulting from
the neutral loss as a ketene of the 9-HSA moiety (m/z 466.3). The existe ce of an alkyl ether bond at
the sn-1 position, which is not subjected to collision-induced dissociation at regular collision energies,
co firms that 9-HSA is esterifying the sn-2 position of the glycerol backbone of the phospholipid [17].
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important to note, however, that the product of oleate hydration in bacteria is 10-HSA, not 9-HSA 
[24,25] and, as indicated above, 9-HSA is the only isomer found at measurable levels in tumors. To 
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Figure 6. Determination of 9-HSA levels in colorectal cancer cell lines. The levels of both free fatty 
acid and esterified forms of 9-HSA in HCT116 cells (left) and HT29 (right) is shown. Data are 
expressed as means ± SEM (n = 3). 
Next, we also examined the possibility that stearic acid, not oleic acid, was the biosynthetic 
precursor of 9-HSA. We labeled the cells with [2H]stearic acid and sought for 9-[2H]HSA by GC/MS 
and LC/MS. Again, our attempts were unsuccessful. Hence, we conclude that neither stearic nor oleic 
acid are biosynthetic precursors of 9-HSA in colon cancer cells. We also tested whether 9-HSA could 
Figure 5. Phospholipid fatty acid composition of human colorectal tumors. The profile of major fatty
acids in healthy normal tissue (black bars) or tumors (open bars) was determined by GC/MS after
converting the fatty acid glyceryl esters into fatty acid methyl esters. 16:1n−x denotes a mix of the n−9
and n−10 isomers, which elute together. Data are expressed as means ± SEM (n = 17).
Some bacteria strains have been found to contain an enzyme, called oleate hydratase, capable
of generating hydroxystearic acid via direct hydration of the double bond of oleic acid [24,25]. It is
important to note, however, that the product of oleate hydration in bacteria is 10-HSA, not 9-HSA [24,25]
and, as indicated above, 9-HSA is the only isomer found at measurable levels in tumors. To investigate
whether 9-HSA is a metabolite of oleic acid in colorectal cancer, we incubated HT-29 or HCT-116
colorectal cancer cells with increasing amounts of [2H]oleic acid, and analyzed the possible appearance
of 9-[2H]HSA by GC/MS and LC/MS at different times. HCT-116 and HT-29 cell lines are well
established models for colon cancer with rapid proliferation rates, which offers greater versatility and
more controlled conditions for assays than primary cultures of cells isolated from tumors, where cellular
heterogeneity may reduce applicability. While both HT-29 and HCT-16 cells readily incorporated
2H-labeled oleic acid into phospholipids, no 2H-labeled HSA could be detected over a wide range of
concentrations (up to 100 µM) and times (up to 40 h). Of note, both cells lines contained measurable
levels of preexisting ‘endogenous’ (i.e., non-labeled) 9-HSA, both as free fatty acid and in esterified
form (Figure 6).
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Next, we also examined the possibility that stearic acid, not oleic acid, was the biosynthetic
precursor of 9-HSA. We labeled the cells with [2H]stearic acid and sought for 9-[2H]HSA by GC/MS
and LC/MS. Again, our attempts were unsuccessful. Hence, we conclude that neither stearic nor
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oleic acid are biosynthetic precursors of 9-HSA in colon cancer cells. We also tested whether 9-HSA
could be produced via non-enzymatic oxidation of oleic acid. Different oxidation methods were
utilized, namely incubating aqueous dispersions of oleic acid (up to 100 µM) with the free radical
generators 2,2′-azobis(2-methylpropionamidine) dihydrochloride, Fenton’s reagent (ferrous sulfate
plus hydrogen peroxide), or just by exposing the oleic acid in air for at least 1 day. In neither case
could 9-HSA be detected, suggesting that significant oxidation of oleic acid to 9-HSA is not attainable
non-enzymatically. In addition, our preliminary attempts at establishing whether bacteria present in
the gut microbiota make 9-HSA have been unsuccessful to this point.
All of the above negative results moved us to consider the possibility that, rather than being
produced endogenously, 9-HSA arises from exogenous, dietary sources. If so, one would expect to
measure significant levels of 9-HSA in serum. This happened to be the case, and we were able to
estimate a 9-HSA concentration of 2.39 ± 0.36 µM in human serum, and 0.38 ± 0.05 µM in fetal calf
serum (Gibco) (mean ± S.E.M., n = 3). These concentrations are sufficient to account for the levels of
9-HSA detected in tumors and adjacent normal tissue on the one hand, and in cultured HT-29 and
HCT-116 cells on the other. Interestingly, 9-HSA in serum was found almost exclusively esterified in
phospholipids, which suggests that the fatty acid may be more efficiently transported and delivered to
cells and tissues in this manner. Consistent with our data suggesting a dietary origin for 9-HSA, studies
by Wilson et al. [26] have demonstrated that the plasma concentration of hydroxy fatty acids increases
in healthy women following their consumption, clearly indicating that they are effectively absorbed.
Recently, a new family of lipids consisting of FAHFA, with important pathophysiological
implications, has been described [11,12]. These compounds are of biomedical interest because
of their beneficial actions on a number of inflammatory and metabolic diseases, and attracted our
attention because they contain 9-HSA as a major constituent [11,12,27]. FAHFA have been shown to be
produced in vivo from preexisting hydroxy fatty acids via a putative acyl-CoA acyltransferase-like
reaction [27,28]. Although the biochemical origin of the constituent hydroxy fatty acid has not been
defined, evidence has been provided that the synthesis is stereospecific, as the R-isomer appears to be
preferred over the S-isomer. This implies again the involvement of enzymes in FAHFA synthesis [29].
We were able to detect three 9-HSA-containing FAHFA in our colorectal tumor samples and adjacent
normal tissue, namely those esterifying oleic, palmitic, and stearic acids: 9-OAHSA (oleic acid ester of
9-hydroxystearic acid), 9-PAHSA (palmitic acid ester of 9-hydroxystearic acid) and 9-SAHSA (stearic
acid ester of 9-hydroxystearic acid), respectively (Figure 7A,B). Strikingly, the amount of FAHFA in
tumors was found to be significantly elevated when compared to normal tissue (Figure 7A,B).
The same three FAHFA species were also found in HCT-116 (Figure 7C) and HT-29 cells (Figure 7D),
albeit in the cell lines the major species was 9-PAHSA, not 9-OAHSA as in tumors. Interestingly, when
both cell lines were incubated with increasing amounts of 9-HSA, the cellular levels of the three FAHFA
increased accordingly (Figure 7C,D). The latter is an important finding because it clearly indicates that
FAHFA formation may constitute a cellular strategy to dampen the cellular level of 9-HSA in the form
of free fatty acid, which is toxic to cells. To assess this possibility, we characterized 9-HSA-induced
cell death in colon cancer cells. Figure 8 shows that incubation of either HCT-116 or HT-29 cells with
9-HSA concentrations ≥50 µM, resulted in marked losses of cell viability, as measured by the CellTiter
96® AQueous One Solution Cell Proliferation Assay kit. Cells exposed to the same concentrations of
oleic acid as a control, experienced no such viability losses. This range of concentrations at which
9-HSA induces cell death is consistent with previous reports utilizing various cell types [6–10].
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Figure 7. Determination of FAHFA levels in tumors and cell lines. (A) Total 9-HSA-containing FAHFA
levels in normal tissue (black bar) or tumor (open bar) is indicated. (B) Identification of distinct FAHFA
molecular species in normal tissue (black bars) and tumor (open bars). (C) FAHFA species present in
HCT-116 cells increase when the cells are incubated with 9-HSA. (D) FAHFA species present in HT-29
cells increase when the cells are incubated with 9-HSA. Data are expressed as means ± SEM (n = 11 for
tumors; n = 3 for cell lines). * Significantly different (p < 0.05) from normal tissue.
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Figure 8. Concentration-de c f the effect of 9-HSA on cell viability. HT-116 cells (left) or HT-29
cells (right) were incubated with the indicated concentrations of 9-HSA (black circles) or oleic acid
(open circles), as a negative control for 24 h. Cell viability was measured with the CellTiter 96® AQueous
One Solution Cell Proliferation Assay kit. Data are expressed as means ± SEM (n = 3).
The eff ct of 9-HSA on casp e-9 fragmentation was analyzed by i l t, nd the results are
shown in Figure 9A. Staurorporine was used in these experiments as a positive control. The results clearly
showed that 9-HSA induced caspase-9 fragmentation. In additio , we noted that treating the cells with
9-HSA also resulted in the caspase-3-dependent cleavage of poly(ADP-ribose) polymerase 1 substrate,
which was obs rv d as early as 4 h after exposure of the cells to the fatty acid, i agreement with previous
estimat s in other lls types [30,31]. Importantly, 9-PAHSA, used at the same concentration as 9-HSA and
under identical experimental conditions, failed to show any effect. Similar results were obtained when
flow cytometry-based detection assays of loss of membrane asymmetry were carried out. HCT-116 and
HT-29 cells were either untreated or treated with 9-HSA or 9-PAHSA (Figure 9B). Untreated cells retained
the same appearance as live cells (without annexin-V or propidium iodide staining), and the same was
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true for the 9-PAHSA treated-cells. In both cases, the upper quadrants of the cytometry analysis (left and
right) for both cell lines, showed less than 5% of cell death due to early or late apoptosis. In contrast,
9-HSA treated-cells showed apoptotic cell death close to 12% (HCT-116) or 20% (HT-29). Collectively,
these data support the concept that incorporation of 9-HSA into FAHFA abrogates the ability of the
hydroxy fatty acid to induce apoptotic cell death.
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Figure 9. Analysis of apoptotic rs in 9-PAHSA (palmitic acid ester of 9-hydroxystearic acid)
and 9-HS -treated HCT-116 and HT-29 cells. (A) Untreated cells or cells treated with either 100 µM
9-HSA or 100 µM 9-PAHSA for 24 h, were harvested and protein was separated by SDS-polyacrylamide
gel electrophoresis, and analyzed by Western blotting. Cleaved fragments of caspase 9 are indicated.
Blots were re-probed for β-actin to confirm equal loading of the samples. (B) Flow cytometry-based
apoptosis detection. Apoptotic changes in plasma membrane were detected by simultaneous staining
with annexin V-fluorescein isothiocyanate (FITC) (FL1) and propidium iodide (PI; FL3). HCT-116 and
HT-29 cells were untreated (Control) or treated with either 100 µM 9-HSA or 100 µM 9-PAHSA for
24 h. Cells were collected, and their green and red fluorescence was measured by flow cytometry.
Live cells are both annexin V and propidium iodide (PI) negative. At early stage of apoptosis, cells
bind annexin V while still excluding PI (upper left quadrant). At late stage of apoptosis, they bind
annexin V-FITC and stain brightly with PI (upper right quadrant). Primary necrotic and some very
late apoptotic cells stain with PI only (lower right quadrant). These data are representative of three
independent experiments.
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3. Materials and Methods
3.1. Reagents
Cell culture medium was from Molecular Probes-Invitrogen (Carlsbad, CA, USA). Organic solvents
(Optima® LC/MS grade) were from Fisher Scientific (Madrid, Spain). Lipid standards were purchased
from Avanti (Alabaster, AL, USA) or Cayman (Ann Arbor, MI, USA). Deuterated fatty acids (stearic-d35
acid and oleic-d34 acid) were from Sigma-Aldrich. SilicaGel thin-layer chromatography plates were
from Macherey-Nagel (Düren, Germany). 9-HSA and 12-HSA were synthesized and provided by Dr.
Alfonso Pérez (Department of Organic Chemistry, University of Valladolid, (Valladolid, Spain). All
other reagents were from Sigma-Aldrich (Madrid, Spain).
3.2. Patients and Sampling Procedures
Samples of Stage I or Stage IIA colorectal cancer, which otherwise would have been discarded,
were obtained at the time of surgery from patients undergoing colon resection at the Clinical Hospital of
the University of Valladolid School of Medicine. Adjacent grossly normal-appearing tissue specimens
to be used as controls were collected from the accompanying normal mucosa, distant at 10–15 cm from
the carcinoma. The study was approved by the Research Ethics Committee of the Clinical Hospital of
the University of Valladolid School of Medicine (date of approval, February 23, 2013), in accordance
with the guidelines established by the Spanish Ministry of Health and the European Union, and in
conformity with the World Medical Association Declaration of Helsinki. Written informed consent
was obtained from each donor. The researchers received the samples in an anonymous manner.
3.3. Cell Lines
The human colon cancer cell lines HCT-116 and HT-29 were provided by Dr. Ana B. Herrero
(Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas,
Salamanca, Spain). They were maintained in Dulbecco’s Modified Eagle medium supplemented with
10% (v/v) fetal bovine serum, 2 mM glutamine, penicillin (100 units/mL), and streptomycin 100 µg/mL.
The cells were incubated at 37 ◦C in a humidified atmosphere of 5% CO2. Cell viability was measured
using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI,
USA), following the manufacturer’s instructions.
3.4. Detection of Apoptosis
The effect of 9-HSA or 9-PAHSA on apoptosis was evaluated over a wide range of concentrations
(1–400 µM). Based on preliminary time-course data, the exposure time was set to 24 h, and apoptosis
was analyzed by labeling with the annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit
(BD Bioscience, San Jose, CA, USA), which recognizes phosphatidylserine exposure on the outer leaflet
of the plasma membrane. After washing the cells, cell fluorescence was quantified by flow cytometry
in FL1 (Gallios; Beckman Coulter, Barcelona, Spain). Data were analyzed with the FlowJo software
version 8.7. Propidium iodide (PI, Sigma-Aldrich, Madrid, Spain) uptake was analyzed by incubating
cells with 50 µg/mL PI in PBS in the dark for 5 min. Fluorescence was quantified by flow cytometry
in FL3. Data were analyzed with FlowJo version 8.7. In parallel to these measurements, the cells,
treated with 9-HSA or 9-PAHSA for the time indicated, were analyzed by immunoblot for the intact
and cleaved forms of caspase-9.
3.5. Immunoblot Analyses
After the different treatments, the cells were lysed in ice-cold buffer containing 20 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 0.5% Triton X-100, 100 mM Na3VO4, 1 mM phenyl methyl sulfonyl fluoride,
and protease inhibitor cocktail (Sigma). Total protein (50 µg) was resolved on 10–12% SDS-PAGE
gels and transferred to a nitrocellulose membrane. After transfer, nonspecific binding sites were
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blocked with 5% defatted dry milk in PBS containing 0.1% Tween-20 at room temperature for 1 h.
The membranes were then probed with the corresponding antibodies, followed by HRP-conjugated
secondary antibodies in blocking solution. β-Actin was used as a load control. The immunoblots were
visualized using enhanced luminescence.
3.6. Real-Time PCR
Total RNA was extracted using Trizol reagent (Ambion-Thermo Fisher, Waltham, MA, USA).
The cDNA templates were synthesized using Verso cDNA synthesis kit (Thermo Fisher Scientific,
Waltham, MA, USA), following the manufacturer’s instructions. Quantitative PCR (qPCR) was carried
out with a 7500 Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA), using Brilliant III
Ultra-Fast SYBR Green qPCR Master Mix (Agilent Technologies, Santa Clara, CA, USA), as previously
described [32].
3.7. Gas Chromatography/Mass Spectrometry (GC/MS) Analyses
Tumor samples were sliced, weighed and homogenized mechanically with a polytron tissue
homogenizer prior to total lipid extraction according to Folch et al. [33]. Cultured cell samples (approx.
107 cells) were washed with PBS, lysed with water, and sonicated in a tip homogenizer twice for
15 s, prior to total lipid extraction according to Bligh and Dyer [34]. The following internal standards
were added before lipid extraction: 10 nmol of 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine,
10 nmol of 1,2,3-triheptadecanoyl-sn-glycerol and 30 nmol of cholesteryl tridecanoate. Lipid classes
were separated by thin-layer chromatography, using n-hexane/diethyl ether/acetic acid (70:30:1, v/v/v)
as the mobile phase [35]. Glycerolipids and glycerophospholipids were transmethylated with 500 µL
of 0.5 M KOH in methanol for 30 min at 37 ◦C, and 500 µL of 0.5 M HCl was added to neutralize. For
the transmethylation of cholesterol esters, the samples were resuspended in 400 µL methyl propionate,
and 600 µL 0.84 M KOH in methanol for 1 h at 37 ◦C. Afterwards, 50 and 1 mL of acetic acid and water,
respectively, were added to neutralize [36–38].
Hydroxylated fatty acids need an extra derivatization step to introduce a trimethylsilyl group that
reduces lability of the hydroxyl groups and makes the molecule volatile for GC/MS analysis. Fatty acid
methyl esters obtained as described above were used as starting material for trimethysilylation. A
total of 150 µL of Tri-Sil HTP (HDMS:TMCS:pyridine) Reagent (Thermo Scientific) was added to the
fatty acid methyl ester extract. Samples were vortexed for 30 s and the derivatization reaction was
carried out for 10 min at room temperature under continuous stirring. The solvent was evaporated and
500 µL water and 800 µL n-hexane was added. After vigorous vortexing for 30 s, the upper organic
layer was saved.
Analysis of fatty acid methyl esters, either derivatized with TMS or not, was carried out using an
Agilent 7890A gas chromatograph coupled to an Agilent 5975C mass-selective detector operated in
electron impact mode (EI, 70 eV) equipped with an Agilent 7693 autosampler and an Agilent DB23
column (60 m length × 250 µm internal diameter × 0.15 µm film thickness) under the conditions
described previously [38,39]. Data analysis was carried out with the Agilent G1701EA MSD Productivity
Chemstation software, revision E.02.00 (Santa Clara, CA, USA).
3.8. Liquid Chromatography/Mass Spectrometry (LC/MS) Analyses
Lipids were extracted according to Bligh and Dyer [34], and the following internal
standards were added: 20 pmol each of 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol,
1,2-dilauroyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine,
1,2-di-heptadecanoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoserine,
1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine,
1,2-di-heptadecanoyl-sn-glycero-3-phosphocholine and 1,2-dinonadecanoyl-sn-glycero-3-phosphocholine.
The samples were redissolved in 50 µL of hexanes/2-propanol/water (42:56:2, v/v/v), and 40 µL was
injected into an Agilent 1260 Infinity high-performance liquid chromatograph equipped with an
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Agilent G1311C quaternary pump and an Agilent G1329B autosampler. The column was a FORTIS
HILIC (150 × 3 mm, 3 µm particle size) (Fortis Technologies, Geston, UK), protected with a Supelguard
LC-Si (20 × 2.1 mm) cartridge (Sigma-Aldrich). The mobile phase consisted of a gradient of solvent A
(hexanes/2-propanol, 30:40, v/v) and solvent B (hexanes/2-propanol/20 mM ammonium acetate in
water, 30:40:7, v/v/v). The gradient started at 75% A from 0 to 5 min, then decreased from 75% A to
40% A at 15 min, from 40% A to 5% A at 20 min, holding at 5% until 40 min, and increasing to 75% at
41 min. The column was then re-equilibrated by holding at 75% A for an additional 14 min before
the next sample injection. The flow rate through the column was fixed at 400 µL/min, and this flow
entered into the electrospray ionization interface of an AB/Sciex QTRAP 4500 hybrid triple quadrupole
mas spectrometer operated in negative ion mode. Source parameters were as follows: ion spray
voltage, −4500 V; curtain gas, 30 psi; nebulizer gas, 50 psi; desolvation gas, 60 psi; temperature, 425 ◦C.
Phospholipid species were detected as [M−H]− ions except for choline phospholipids, which were
detected as [M+CH3COO−]− adducts, and were identified by comparison with previously published
data [40–46].
FAHFA analysis by LC/MS was carried out as described by Zhang et al. [47]. Briefly, total lipid
extracts were redissolved in 500 µL chloroform and loaded into solid-phase extraction silica columns
(Supelco Discovery DSC-Si, Sigma-Aldrich) that had been previously conditioned by passing 15 mL
n-hexane through them. Neutral lipids were eluted with 5 mL n-hexane/ethyl acetate (95:5, by vol.).
FAHFA were eluted with 4 mL ethyl acetate and evaporated under a nitrogen stream. Quantitative
isolation of FAHFAs by this method was confirmed by using an authentic 9-PAHSA standard. The
FAHFA fraction was redissolved in 50 µL methanol, and 40 µL was injected into an Agilent 1260
Infinity high-performance liquid chromatograph equipped with an Agilent G1311C quaternary pump
and an Agilent G1329B autosampler. The column was a reversed-phase C18 column (250 × 2 mm, 5
µm particle size, Knauer, Berlin, Germany). Total flow through the column was 400 µL/min, with 93:7
MeOH:H2O with 5 mM ammonium acetate and 0.01% ammonium hydroxide as solvent. Total run time
was 60 min. The LC system was coupled to an AB/Sciex API 4500 Q-TRAP hybrid triple quadrupole
mas spectrometer operated in negative ion mode. Source parameters were as follows: ion spray
voltage, −4500 V; curtain gas, 30 psi; nebulizer gas, 50 psi; desolvation gas, 60 psi; temperature, 500 ◦C.
For the quantitative measurement of 9-HSA-containing FAHFA species (especially those containing
palmitic, palmitoleic, stearic, oleic and linoleic acids), the instrument was set to multiple reaction
monitoring mode, selecting three transitions for each FAHFA: parent ion→ 299.3 (9-HSA), parent ion
→ 281.3 (9-HSA as water loss) and parent ion→ m/z of esterified fatty acid as carboxylate ion. Only
peaks with a signal-to-noise ratio higher than five were quantified.
3.9. Statistical Analysis
Data are expressed as means ± SE of the number of independent determinations indicated.
Student’s t-test was applied for statistical analysis of the data, with p < 0.05 taken as
statistically significant.
4. Conclusions
We report in this study that human colorectal tumors contain significantly lower levels of 9-HSA
than adjacent normal tissue, suggesting that highly proliferating cells such as those of tumors possess
mechanisms to keep 9-HSA at low levels and, in this manner, inactivate an endogenous brake to
uncontrolled cell division. Our results add to this concept by demonstrating that colorectal cancer lines
make significant amounts of various FAHFA when supplied with 9-HSA. Further, we made the key
observation that, while 9-HSA is pro-apoptotic, 9-HSA-containing FAHFA is not. Thus, in addition to
its well described roles as anti-diabetic and anti-inflammatory lipids, FAHFA may be produced as an
anti-apoptotic strategy to ameliorate the pro-apoptotic effects of hydroxy fatty acids accumulating
in cells.
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In accord with all the above, we demonstrate as well that FAHFA content in human tumor
samples is significantly elevated when compared with adjacent normal tissue, clearly suggesting a
pathophysiological role, such as preventing the pro-apoptotic effects of 9-HSA. Thus, FAHFA synthesis
may occur at proliferative tumor stages where there is a predominance of mitosis over apoptosis and,
in opposition, cells may activate FAHFA hydrolysis at times of declining cell death, thus regulating the
cell cycle via lipid signaling. The finding that FAHFA molecules are found in tumors shows that this
mechanism may work in vivo and, at the same time, provides an interesting starting point from which
to consider these lipids as pharmacological targets, focusing on the specific hydrolysis of FAHFA that
provides apoptotic hydroxyacids in situ.
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